$CUE
Cue Biopharma Inc

2018 Q2 Form 10-Q Financial Statement

#000156459018013461 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q4
Revenue $172.0K $190.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.220M $1.700M $1.410M
YoY Change 124.24% 91.01% 80.77%
% of Gross Profit
Research & Development $5.414M $5.819M $8.900M
YoY Change 63.07% 136.45% 345.0%
% of Gross Profit
Depreciation & Amortization $195.0K $167.0K $130.0K
YoY Change 95.0% 149.25% 116.67%
% of Gross Profit
Operating Expenses $7.644M $7.522M $10.44M
YoY Change 73.22% 124.54% 267.61%
Operating Profit -$7.472M -$7.522M
YoY Change 69.32% 124.54%
Interest Expense $170.0K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $172.0K -$1.000K
YoY Change
Pretax Income -$7.300M -$7.510M -$10.44M
YoY Change 65.53% 124.18% 267.61%
Income Tax
% Of Pretax Income
Net Earnings -$7.300M -$7.523M -$10.44M
YoY Change 65.42% 124.57% 267.61%
Net Earnings / Revenue -4244.19% -3959.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$358.2K -$373.3K -$627.4K
COMMON SHARES
Basic Shares Outstanding 20.13M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.80M $53.20M $63.53M
YoY Change 518.92%
Cash & Equivalents $45.94M $53.10M $63.53M
Short-Term Investments $100.0K $100.0K $0.00
Other Short-Term Assets $3.500M $2.800M $1.500M
YoY Change 288.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.25M $55.93M $65.07M
YoY Change 500.61%
LONG-TERM ASSETS
Property, Plant & Equipment $2.763M $2.423M $1.691M
YoY Change 62.53%
Goodwill
YoY Change
Intangibles $175.0K $175.0K $175.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $800.0K $198.3K
YoY Change 350.0%
Total Long-Term Assets $3.864M $3.397M $1.889M
YoY Change 93.2%
TOTAL ASSETS
Total Short-Term Assets $49.25M $55.93M $65.07M
Total Long-Term Assets $3.864M $3.397M $1.889M
Total Assets $53.11M $59.33M $66.95M
YoY Change 420.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $546.0K $1.200M $1.659M
YoY Change -31.75%
Accrued Expenses $1.124M $300.0K $1.151M
YoY Change 60.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.963M $4.100M $5.347M
YoY Change 85.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.963M $4.100M $5.347M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.882M $4.084M $5.347M
YoY Change 142.63%
SHAREHOLDERS EQUITY
Retained Earnings -$47.63M -$40.34M -$32.82M
YoY Change
Common Stock $96.86M $94.43M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.23M $55.24M $61.61M
YoY Change
Total Liabilities & Shareholders Equity $53.11M $59.33M $66.95M
YoY Change 420.73%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q4
OPERATING ACTIVITIES
Net Income -$7.300M -$7.523M -$10.44M
YoY Change 65.42% 124.57% 267.61%
Depreciation, Depletion And Amortization $195.0K $167.0K $130.0K
YoY Change 95.0% 149.25% 116.67%
Cash From Operating Activities -$6.460M -$9.759M -$1.890M
YoY Change 104.43% 182.05% -5.97%
INVESTING ACTIVITIES
Capital Expenditures -$760.0K $673.0K -$10.00K
YoY Change 80.95% 21.04% -90.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$760.0K -$673.0K -$10.00K
YoY Change 80.95% 20.18% -90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 62.04M
YoY Change -100.0% 313.05%
NET CHANGE
Cash From Operating Activities -6.460M -9.759M -1.890M
Cash From Investing Activities -760.0K -673.0K -10.00K
Cash From Financing Activities 0.000 62.04M
Net Change In Cash -7.220M -10.43M 60.14M
YoY Change 100.56% 159.5% 365.84%
FREE CASH FLOW
Cash From Operating Activities -$6.460M -$9.759M -$1.890M
Capital Expenditures -$760.0K $673.0K -$10.00K
Free Cash Flow -$5.700M -$10.43M -$1.880M
YoY Change 108.03% 159.76% -1.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 cue Research And Development Contract Advances Current
ResearchAndDevelopmentContractAdvancesCurrent
1383000
CY2017Q4 cue Research And Development Contract Advances Current
ResearchAndDevelopmentContractAdvancesCurrent
852000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
884000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403000
CY2018Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
510000
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
226000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
55929000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2423000
CY2018Q1 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
175000
CY2018Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
50000
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
50000
CY2017Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
175000
CY2018Q1 cue Long Term Service Contract Noncurrent
LongTermServiceContractNoncurrent
23000
CY2017Q4 cue Long Term Service Contract Noncurrent
LongTermServiceContractNoncurrent
23000
CY2018Q1 us-gaap Deposit Assets
DepositAssets
776000
CY2018Q1 us-gaap Assets
Assets
59326000
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1166000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1331000
CY2018Q1 cue Accrued Compensation And Related Expenses Current
AccruedCompensationAndRelatedExpensesCurrent
259000
CY2017Q4 cue Accrued Compensation And Related Expenses Current
AccruedCompensationAndRelatedExpensesCurrent
857000
CY2018Q1 cue Research And Development Collaboration Agreement Deferred Credit
ResearchAndDevelopmentCollaborationAgreementDeferredCredit
2309000
CY2017Q4 cue Research And Development Collaboration Agreement Deferred Credit
ResearchAndDevelopmentCollaborationAgreementDeferredCredit
2500000
CY2018Q1 cue Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
341000
CY2017Q4 cue Research And Development Contract Liabilities Current
ResearchAndDevelopmentContractLiabilitiesCurrent
623000
CY2018Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
9000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
36000
CY2018Q1 us-gaap Liabilities
Liabilities
4084000
CY2017Q4 us-gaap Liabilities
Liabilities
5347000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20130766
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53102000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63534000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40344000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
55242000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59326000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20130766
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20130766
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
7522000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3350000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7522000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3350000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-7523000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3350000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20064000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10636000
CY2018Q1 us-gaap Depreciation
Depreciation
167000
CY2017Q1 us-gaap Depreciation
Depreciation
67000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1158000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
543000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2461000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1703000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
889000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5819000
CY2018Q1 cue Deferred Rent
DeferredRent
27000
CY2017Q1 cue Deferred Rent
DeferredRent
27000
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to determine candidates for clinical testing, the results of clinical testing and trial activities of the Company&#8217;s product candidates, the Company&#8217;s ability to obtain regulatory approval to market its product candidates, the Company&#8217;s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company&#8217;s product candidates if approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates, and the Company&#8217;s ability to raise capital. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has no commercially approved product candidates and there can be no assurance that the Company&#8217;s research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval, as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property. </p></div>
CY2018Q1 cue Increase Decrease In Research And Development Contract Advances
IncreaseDecreaseInResearchAndDevelopmentContractAdvances
-531000
CY2017Q1 cue Increase Decrease In Research And Development Contract Advances
IncreaseDecreaseInResearchAndDevelopmentContractAdvances
-423000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
481000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20000
CY2018Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-1060000
CY2017Q1 us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-101000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-390000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76000
CY2018Q1 cue Increase Decrease In Accrued Compensation And Related Expense
IncreaseDecreaseInAccruedCompensationAndRelatedExpense
-599000
CY2017Q1 cue Increase Decrease In Accrued Compensation And Related Expense
IncreaseDecreaseInAccruedCompensationAndRelatedExpense
-77000
CY2018Q1 cue Increase Decrease In Research And Development Contract Liabilities
IncreaseDecreaseInResearchAndDevelopmentContractLiabilities
-282000
CY2018Q1 cue Increase Decrease In Research And Development Agreement Deferred Credits
IncreaseDecreaseInResearchAndDevelopmentAgreementDeferredCredits
-191000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9759000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3464000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
673000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-673000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-556000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10432000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4020000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14926000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10906000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
227000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
CY2017Q1 cue Accrual Of Deferred Offering Costs
AccrualOfDeferredOfferingCosts
76000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with United States Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the accounting for potential liabilities, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the impairment of long-lived assets and intangibles. Actual results could differ from those estimates. </p></div>
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
661000
CY2018Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
14.05
CY2018Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2017Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2018Q1 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2018Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2018Q1 cue Number Of Commercial Approved Product Candidates
NumberOfCommercialApprovedProductCandidates
0
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4009000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2206000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3251000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2352000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
828000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0243
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0262
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.820
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.830
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2732000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
25000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2757000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
818000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.65
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.18
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.13
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M3D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M7D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M12D
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1158000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
543000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10219000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8941000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2595000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3752000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4661000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1553000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
12561000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
670000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
493000

Files In Submission

Name View Source Status
0001564590-18-013461-index-headers.html Edgar Link pending
0001564590-18-013461-index.html Edgar Link pending
0001564590-18-013461.txt Edgar Link pending
0001564590-18-013461-xbrl.zip Edgar Link pending
cue-10q_20180331.htm Edgar Link pending
cue-20180331.xml Edgar Link completed
cue-20180331.xsd Edgar Link pending
cue-20180331_cal.xml Edgar Link unprocessable
cue-20180331_def.xml Edgar Link unprocessable
cue-20180331_lab.xml Edgar Link unprocessable
cue-20180331_pre.xml Edgar Link unprocessable
cue-ex311_117.htm Edgar Link pending
cue-ex312_116.htm Edgar Link pending
cue-ex321_118.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending